Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types Of Gastrointestinal Cancer. Gastroenterology. 2020;159:335-349.e15.
Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–31.
Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–79.
Ozasa K, Kurata JH, Higashi A, Hayashi K, Inokuchi H, Miki K, et al. Helicobacter pylori infection and atrophic gastritis: a nested case-control study in a rural town in Japan. Dig Dis Sci. 1999;44:253–6.
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on Cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12:989–95.
Tahara T, Arisawa T, Shibata T, Wang FY, Nakamura M, Sakata M, et al. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion. 2007;75:54–61.
Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.
Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One. 2012;7:e36275.
Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002;3:662–73.
Ding WJ, Fang JY, Chen XY, Peng YS. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig Dis Sci. 2008;53:2083–9.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402.
Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncol Rep. 2008;19:223–8.
Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol. 2009;70:547–51.
Li H, Li W, Liu S, Zong S, Wang W, Ren J, et al. DNMT1, DNMT3A and DNMT3B polymorphisms associated with gastric cancer risk: a systematic review and meta-analysis. EBioMedicine. 2016;13:125–31.
Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with helicobacter pylori infection and in gastric cancer. Gut. 2003;52:502–6.
Tahara T, Arisawa T, Shibata T, Nakamura M, Yoshioka D, Okubo M, et al. Increased number of methylated CpG islands correlates with helicobacter pylori infection, histological and serological severity of chronic gastritis. Eur J Gastroenterol Hepatol. 2009;21:613–9.
Rizos H, Darmanian AP, Mann GJ, Kefford RF. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene. 2000;19:2978–85.
Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene. 2001;20:7104–9.
Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, et al. Increased number of CpG island hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa correlates with higher risk of gastric cancer. Digestion. 2010;82:27–36.
Jing W, Otsuka T, Nakamura M, Sakurai N, Takano H, Hayashi T, et al. Association of genetic polymorphisms in DNMT3A with the progression of gastric mucosal atrophy and susceptibility to gastric cancer in Japan. Oncol Lett. 2019;17:3482–8.
Tahara T, Shibata T, Nakamura M, Okubo M, Yamashita H, Yoshioka D, et al. Polymorphisms of DNA repair and xenobiotic genes predispose to CpG island methylation in non-neoplastic gastric mucosa. Helicobacter. 2011;16:99–106.
Poi MJ, Knobloch TJ, Li J. Deletion of RDINK4/ARF enhancer: a novel mutation to "inactivate" the INK4-ARF locus. DNA Repair. 2017;57:50–5.
Gozuacik D, Kimchi A. DAPk protein family and cancer. Autophagy. 2006;2:74–9.
Shenoy S. CDH1 (E-cadherin) mutation and gastric Cancer: genetics, molecular mechanisms and guidelines for management. Cancer Manag Res. 2019;11:10477–86.
Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H. CpG island hypermethylation of tumor-suppressor genes in H pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter. 2008;13:35–41.
Li W, Chen BF. Aberrant DNA methylation in human cancers. J Huazhong Univ Sci Technolog Med Sci. 2013;33:798–804.
Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 2012;22:407–19.
Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999;190:1595–604.
Fan H, Liu D, Qiu X, Qiao F, Wu Q, Su X, et al. A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma. BMC Med. 2010;8:12.